New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pregabalin 75mg;   - capsule - 75 mg - active: pregabalin 75mg   excipient: colloidal silicon dioxide   gelatin   iron oxide red lactose monohydrate maize starch purified talc purified water   sodium laurilsulfate   tekprint black sw-9008 tekprint black sw-9009 titanium dioxide  

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 100mg;  ;   - film coated tablet - 100 mg - active: topiramate 100mg     excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow ys-1-6370-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 200mg;  ;   - film coated tablet - 200 mg - active: topiramate 200mg     excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink ys-1-1456-g as opadry pink ys-1-1759-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 25mg;   - film coated tablet - 25 mg - active: topiramate 25mg   excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 50mg;  ;   - film coated tablet - 50 mg - active: topiramate 50mg     excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow ys-1-6370-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 15mg;  ;   - capsule - 15 mg - active: topiramate 15mg     excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 25mg;  ;   - capsule - 25 mg - active: topiramate 25mg     excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 50mg;  ;   - capsule - 50 mg - active: topiramate 50mg     excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 100mg;  ;   - film coated tablet - 100 mg - active: lacosamide 100mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry yellow 85f38040 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 150mg;  ;   - film coated tablet - 150 mg - active: lacosamide 150mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry tan 85f27043 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.